An explainer on the oral version of Wegovy and the weight loss results reported for it. Only the headline is available, so check the source for details.
Recap by typeshit. Full story at Philstar Life.
A short clip from obesity doctor Nadolsky with his three pointers for people about to begin GLP-1 treatment. The details are in the video.
A general explainer on how GLP-1 receptor agonists affect blood sugar and appetite, with advice on support while taking them.
A sponsored-style look at compounded tirzepatide and semaglutide through telehealth firm Mochi Health, noting compounded drugs aren't FDA approved for safety or quality.
Among the items: Walmart plans free GLP-1 diabetes drugs for employees in 2027, and Verdiva Bio dropped a phase II oral GLP-1 study citing market changes.
Pooling four studies with confirmed first-trimester exposure, researchers found an odds ratio of 0.99 for major malformations, though they flag confounding and comparator limits.
Miami Herald looks at how oral peptide drugs are designed to get past the gut intact and reach specific targets in the body.
Loading…